Lung Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The autopsied lung tumors harbored ALK G1202R (c. 3604 G>A) and the right renal metastasis harbored ALK G1202R (c. 3604 G>C); the mutation thus comprised different codon changes.
|
31374369 |
2019 |
Lung Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Herein, we newly identified that truncated form of CHL1 is produced and released from lung tumor tissue in a mouse model expressing human EML4-ALK fusion gene.
|
29775614 |
2018 |
Lung Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Most anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung tumors initially respond to small-molecule ALK inhibitors, but drug resistance often develops.
|
29505033 |
2018 |
Lung Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The lung tumor cells were subjected to fluorescent in situ hybridization and highly sensitive immunohistochemical staining for the ALK protein, both of which produced positive results.
|
28093881 |
2017 |
Lung Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Analysis of ALK translocations in the primary lung tumor would be suitable for planning the use of a TKI for advanced NSCLC, but it would be better to detect metastasis specimens as ALK negative specimens if both primary and metastatic specimens have developed.
|
29312572 |
2017 |
Lung Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These studies may guide the development of comprehensive treatment strategies that take into consideration the various approaches ALK-positive lung tumors use to withstand therapeutic insult.
|
26719536 |
2016 |
Lung Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found that lung tumors containing ALK rearrangements induced an immunosuppressive microenvironment, regulating the expression of PD-L1 on the surface of lung tumor cells.
|
26419961 |
2015 |
Lung Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CCR 20th Anniversary Commentary: Molecular Pathology of ALK-Rearranged Lung Tumors.
|
26626570 |
2015 |
Lung Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We observed enrichment of gene signatures associated with several resistance drivers (including P2Y receptors) in crizotinib-resistant ALK-rearranged lung tumors compared to treatment-naive controls, supporting a role for these identified mechanisms in clinical ALK inhibitor resistance.
|
25759024 |
2015 |
Lung Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We apply TRUP to RNA-seq data of different tumor types, and find it to be more sensitive than alternative tools in detecting chimeric transcripts, such as secondary rearrangements in EML4-ALK-positive lung tumors, or recurrent inactivating rearrangements affecting RASSF8.
|
25650807 |
2015 |
Lung Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The novel 1A4 antibody represents a promising candidate for screening lung tumors for the presence of ALK rearrangements.
|
25789835 |
2015 |
Lung Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
ALK translocation, occurring at a frequency of 6.8% in Chinese patients, defines a unique molecular subgroup of lung tumors.
|
24775606 |
2014 |
Lung Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A comparison of immunohistochemical assays and FISH in detecting the ALK translocation in diagnostic histological and cytological lung tumor material.
|
24787965 |
2014 |
Lung Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A subgroup of anaplastic lymphoma kinase (ALK)-rearranged lung tumours can respond to ALK inhibitors.
|
22735679 |
2012 |
Lung Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Immunohistochemistry has been proposed as a specific and sensitive method to identify EGFR mutations or ALK rearrangements in lung tumours.
|
22100693 |
2012 |
Lung Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Recent evidence suggests that the observed clinical distinctions between lung tumors in smokers and never smokers (NS) extend beyond specific gene mutations, such as EGFR, EML4-ALK, and KRAS, some of which have been translated into targeted therapies.
|
22412972 |
2012 |
Lung Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
EML4-ALK adenocarcinomas constitute a new molecular subgroup of lung tumours that respond very well to crizotinib, an ALK inhibitor.
|
22153831 |
2012 |
Lung Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Using specific and sensitive IHC assays, we analyzed the expression of anaplastic lymphoma kinase (ALK), EGFR L858R, and EGFR E746-A750del mutations in a subset of lung tumors, including those expressing ROS1.
|
22661537 |
2012 |
Lung Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this article we review the potential role that ALK may have in lung tumor origin, the methodology to detect the different molecular alterations, and the most important clinical aspects of ALK alterations in NSCLC patients.
|
22584871 |
2012 |
Lung Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients.
|
20979469 |
2010 |
Lung Neoplasms
|
0.100 |
GeneticVariation
|
group |
LHGDN |
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.
|
18451166 |
2008 |
Lung Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
|
18166835 |
2008 |
Lung Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
EML4-ALK fusion lung cancer: a rare acquired event.
|
18320074 |
2008 |
Lung Neoplasms
|
0.100 |
GeneticVariation
|
group |
LHGDN |
Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.
|
18593892 |
2008 |
Lung Neoplasms
|
0.100 |
AlteredExpression
|
group |
LHGDN |
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
|
18594010 |
2008 |